BIOSPECIFICS TECHNOLOGIES CORP Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-06: Form 8-K; Period of report 2016-12-05; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2016-11-21: Form 8-K; Period of report 2016-11-18; Description 8.01 Other Events; Details 8.01.
- 2016-11-14: Form 8-K; Period of report 2016-11-11; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2016-11-09: Form 8-K; Period of report 2016-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-06 | 8-K | 2016-12-05 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning December 5, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-11-21 | 8-K | 2016-11-18 | 8.01 Other Events | 8.01 On November 17, 2016, BioSpecifics announced positive data from a Phase 2b study of CCH for the treatment of cellulite, or edematous fibrosclerotic panniculopathy. | form8k.htm |
| 2016-11-14 | 8-K | 2016-11-11 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning November 11, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-11-09 | 8-K | 2016-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2016, the Company announced its financial and operating results for the fiscal quarter ended September 30, 2016. | form8k.htm |
| 2016-11-07 | 8-K | 2016-11-07 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 1, 2016, the Company renewed its Agreement of Lease (the “Renewed Lease”) with 35 Wilbur Street Associates, LLC (the “Landlord”) for the Company’s administrative headquarters located at 35 Wilbur Street, Lynbrook, New York 11563 (the “Premises”). | form8k.htm |
| 2016-08-15 | 8-K | 2016-08-15 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning August 15, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-08-10 | 8-K | 2016-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2016, the Company announced its financial and operating results for the fiscal quarter ended June 30, 2016. | form8k.htm |
| 2016-07-01 | 8-K | 2016-07-01 | 1.04 Mine Safety - Reporting of Shutdowns and Patterns of Violations; 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning July 1, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-06-13 | 8-K | 2016-06-13 | 8.01 Other Events | 8.01 On June 13, 2016, BioSpecifics announced top-line results from a placebo-controlled, double-blinded Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. | form8k.htm |
| 2016-06-03 | 8-K | 2016-06-03 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2016 annual meeting of stockholders of the Company (the “2016 Annual Meeting”) was held on June 2, 2016. | form8k.htm |
| 2016-05-31 | 8-K | 2016-05-31 | 8.01 Other Events | form8k.htm | |
| 2016-05-27 | 8-K | 2016-05-27 | 1.01 Entry into a Material Definitive Agreement; 3.03 Material Modification to Rights of Security Holders | 1.01 On May 27, 2016, the Company entered into an amendment (the “Amendment”) to the Rights Agreement, dated as of May 14, 2002 and previously amended June 19, 2003, February 3, 2011, and again on March 5, 2014, between the Company and Worldwide Stock Transfer, LLC (successor in interest to OTC Corporate Transfer Service Company), as rights agent (the “Rights Agreement”). 3.03 The information set forth under “Item 1.01 Entry into a Material Definitive Agreement” of this Current Report on Form 8-K is incorporated into this Item 3.03 by reference. | form8k.htm |
| 2016-05-18 | 8-K | 2016-05-18 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning May 18, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-05-10 | 8-K | 2016-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2016, the Company announced its financial and operating results for the fiscal quarter ended March 31, 2016. | form8k.htm |
| 2016-03-14 | 8-K | 2016-03-14 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning March 14, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-03-14 | 8-K | 2016-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2016, the Company announced its financial and operating results for the fiscal quarter and full year ended December 31, 2015. | form8k.htm |
| 2016-03-07 | 8-K | 2016-03-07 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning March 7, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-02-26 | 8-K | 2016-02-26 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning February 26, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-02-11 | 8-K | 2016-02-11 | 8.01 Other Events | 8.01 The Company will hold its 2016 annual meeting of stockholders (the “Annual Meeting”) on Thursday, June 2, 2016 at 11:00 a.m. | form8k.htm |
| 2016-02-08 | 8-K | 2016-02-08 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning February 8, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-02-05 | 8-K | 2016-02-05 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure | 1.01 On February 1, 2016, the Company and Endo Global Ventures, a Bermuda unlimited liability company (“Endo Global Ventures”) entered into the First Amendment to Second Amended and Restated Development and License Agreement (the “First Amendment”) to amend certain provisions of the Second Amended and Restated Development and License Agreement, by and between the Company and Auxilium Pharmaceuticals, Inc. (“Auxilium”), dated as of August 31, 2011 (the “License Agreement”), which was filed with the Securities and Exchange Commission (the “SEC”) on September 1, 2011 as Exhibit 10.1 to a Current Report on Form 8-K. Auxilium subsequently assigned the License Agreement to Auxilium Bermuda ULC. 7.01 The Company will recognize the income resulting from the $8.25 million dollar payment over time based on sales by non-affiliated sublicensees of Endo Global Ventures outside of the United States. | form8k.htm |
| 2016-01-22 | 8-K | 2016-01-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 19, 2016, the Compensation Committee of the Board of Directors of the Company (the “Committee”) established the annual base salary and target bonus amounts for 2016 for Thomas L. Wegman, President of the Company. | form8k.htm |
| 2016-01-19 | 8-K | 2016-01-19 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning January 19, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |
| 2016-01-11 | 8-K | 2016-01-11 | 7.01 Regulation FD Disclosure | 7.01 Officers and representatives of the Company will present to various investors and stockholders beginning January 11, 2016 using the presentation materials furnished as Exhibit 99.1 hereto and which are incorporated herein by reference. | form8k.htm |